Fortress Biotech Inc’s (NASDAQ:FBIO) partner company, Cyprium Therapeutics Inc announced results from an efficacy and safety analysis of data integrated from two CUTX-101…
Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") partner company, with support from its licensing partner Sentynl Therapeutics, Inc. ("Sentynl"), a
AstraZeneca Plc (NASDAQ:AZN) will take complete control of Caelum Biosciences in a deal worth up to $500 million, sharpening its focus on rare-disease…
Today's 5 Stock Ideas:
CarMax (KMX) - The company reports Q2 earnings results tomorrow on Thursday, Sept. 30th.
Camber Energy (CEI) - The most searched ticker on Benzinga Pro over the last 24
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 28)